Sincalide
データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます
25126-32-3CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@@H](N)CC(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=OIZTQOLKUZKXIRV-YRVFCXMDSA-NSincalide is an oligopeptide.
25126-32-3DTXSID7048617CHEMBL1121CHEBI:135946Breast Feeding; Lactation; Milk, Human; Gastrointestinal Hormones; Cholecystokinin; Diagnostic Agents
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Drug Induced Liver Injury Rank (DILIrank 2.0)
Sincalide
vNo-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
V - Various
QV - Various
Following an intravenous (bolus) injection of 0.02 mcg/kg of sincalide, maximal contraction of the gallbladder occurred in 5 to 15 minutes. Sincalide reduced gallbladder radiographic size by at least 40%, generally considered satisfactory contraction.
When injected intravenously, sincalide produces a substantial reduction in gallbladder size by causing this organ to contract. The evacuation of bile that results is similar to that which occurs physiologically in response to endogenous cholecystokinin. Like cholecystokinin, sincalide stimulates pancreatic secretion; concurrent administration with secretin increases both the volume of pancreatic secretion and the output of bicarbonate and protein (enzymes) by the gland. This combined effect of secretin and sincalide permits the assessment of specific pancreatic function through measurement and analysis of the duodenal aspirate.
M03GIQ7Z6P
SINCALIDE
Chemical Structure [CS] - Cholecystokinin
Established Pharmacologic Class [EPC] - Cholecystokinin Analog
Sincalide is a Cholecystokinin Analog.
SINCALIDE
The intravenous (bolus) administration of sincalide causes a prompt contraction of the gallbladder that becomes maximal in 5 to 15 minutes, as compared with the stimulus of a fatty meal which causes a progressive contraction that becomes maximal after approximately 40 minutes.
Limited information is available on the route of elimination of sincalide
Limited information is available on the volume of distribution of sincalide.
使用Sincalide is used in the biological studies in the preparation of opioid receptors agonistic and CCK receptor antagonistic activity.
一般的な説明It was thought originally that cholecystokinin and pancreozyminwere two different hormones. Cholecystokinin wasthought to be responsible for contraction of the gallbladder,whereas pancreozymin was believed to induce secretion ofpancreatic enzymes. It is now clear that both actions arecaused by a single 33-residue polypeptide, referred to ascholecystokinin–pancreozymin (CCK-PZ). CCK-PZ is secretedin the blood in response to the presence of food in theduodenum, especially long-chain fatty acids. The fiveCOOH-terminal amino acid residues are identical with thosein gastrin. The COOH-terminal octapeptide retains full activityof the parent hormone.